An interventional study of Patients suffering from the co-occurrence of ADHD and addiction(s) in Attention Deficit Hyperactivity Disorder, Behavior Hyperactive and Behavior Disorders, sponsored by Nantes University Hospital. Recruiting at 3 sites in France. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-04-17.
Sponsored by Nantes University Hospital · Not applicable, Interventional, and Other
The ADA cohort aims for the systematic and standardized collection of sociodemographic, clinical and neuropsychological data, during 2 visits (inclusion and 12 months), from patients suffering from the co-occurrence of ADHD (Attention Deficit Hyperactivity Disorder) and addiction(s), in addition to the treatment as usual adapted to each situation.
Information on the study and diagnosis of ADHD will be carried out during a medical evaluation consultation, as part of routine care.
The two research visits (inclusion and at 12 months) will be added by the research and will each include:
1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 296 are open to participants now.
This study's planned enrollment of 80 is above the median of 71 across 1,437 interventional studies indexed under Attention Deficit Disorder with Hyperactivity.
Browse Attention Deficit Disorder with Hyperactivity studies →Nantes University Hospital is the lead sponsor of 839 studies on the registry; 195 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria :
Determination of the neuropsychological profile
Other: Patients suffering from the co-occurrence of ADHD and addiction(s)
All eligible patients over 18 years, presenting both a diagnosis of ADHD and a diagnosis of at least one addictive disorder (SUD, AUD (Alcohol Use Disorder) and/ or behavioral addiction), starting care in one of the three participating centers, and meeting the indication for treatment with MPH according to European recommendations (J. J. S. Kooij et al., 2019)
Functional impairment
Weiss Functional Impairment Rating Scale (WFIRS-S) (scores of the 7 domains and total score)
Time frame: Inclusion and 12-month follow-up
Type and severity of ADHD
Diagnostiscal Interview Voor Attention deficit hyperactivity disorder (DIVA-5)
Time frame: Inclusion
Symptoms of ADHD
Adult ADHD Self-Report Scale Symptom Checklist (ASRS-1.1) (inattention and hyperactivity/impulsivity scores)
Time frame: Inclusion and 12-month follow-up
Addictive disorders - substance use disorders (including tobacco, alcohol and other substances)
Mini International Neuropsychiatric Interview- Simplified for Diagnostic and Statistical Manual (DSM)-5 (MINI-S)
Time frame: Inclusion and 12-month follow-up
Addictive disorders - gambling disorder
National Opinion research center DSM Screen for gambling problems (NODS)
Time frame: Inclusion and 12-month follow-up
Addictive disorders - sex addiction
Structured interview adapted from the NODS to explore the diagnostic criteria proposed by Carnes et al in 2012
Time frame: Inclusion and 12-month follow-up
Addictive disorders - gambling disorder
Structured interview adapted from the NODS to explore the diagnostic criteria proposed in the third section of the DSM-5 for the Internet gaming disorder
Time frame: Inclusion and 12-month follow-up
Addictive disorders - eating addiction
Yale Food Addiction Scale (YFAS 2.0)
Time frame: Inclusion and 12-month follow-up
Psychiatric disorders
MINI-S
Time frame: Inclusion and 12-month follow-up
Neuropsychological profile - selective attention
D2-R test (CCT standard score, E% standard score and CC standard score)
Time frame: Inclusion and 12-month follow-up
Neuropsychological profile - short-term and working memory
Digit memory test (standardized scores of numbers of items correctly recalled (direct order, indirect order, ascending order, total), span sizes (direct order, indirect order, ascending order))
Time frame: Inclusion and 12-month follow-up
Neuropsychological profile - inhibition
Stroop test (standardized execution times (naming condition, interference condition), standardized numbers of uncorrected errors (naming condition, interference condition), and standardized interference score)
Time frame: Inclusion and 12-month follow-up
Neuropsychological profile - spontaneous flexibility
Verbal fluency test (standardized scores for the number of words cited and the number of errors, in both conditions (literal and categorical))
Time frame: Inclusion and 12-month follow-up
Neuropsychological profile - planning
Zoo test (total profile score)
Time frame: Inclusion and 12-month follow-up
Psychopathological profile - impulsivity
Urgency, Premeditation (lack of), Perseverance (lack of), Sensation seeking impulsivity behavior scale (UPPS-P) (5 scores)
Time frame: Inclusion and 12-month follow-up
Psychopathological profile - emotional dysregulation
Difficulties in Emotion Regulation Scale (DERS-16) (5 scores and total score)
Time frame: Inclusion and 12-month follow-up
Psychopathological profile - sensorial profile
Sensory profile of Winnie Dunn - adult version (category and raw scores in the 4 quadrants)
Time frame: Inclusion and 12-month follow-up
Psychopathological profile - self-esteem
Rosenberg Self-Esteem Scale (RSES) (total score)
Time frame: Inclusion and 12-month follow-up
Quality of life survey
World Health Organization Quality Of Life (WHOQoL-26) (4 scores)
Time frame: Inclusion and 12-month follow-up
Care received
Effective implementation of treatment with MPH (yes/no) or atomoxetine (yes/no), If no, reasons for not implementing it (for MPH), Care provided (Cognitive remediation / behavioral and cognitive therapy / psychoeducation / other psychosocial intervention (details) / other drug treatment), Reported compliance and misuse for MPH and atomoxetine, Reported compliance for non-drug care, Tolerance: numerical scale from 0 to 10 for the evaluation of the main adverse effects (for MPH and for atomoxetine).
Time frame: 12-month follow-up
Personal and family medical history
List of somatic, psychiatric and addictive disorders for personal history, list of psychiatric and addictive disorders for family history
Time frame: Inclusion
Sociodemographics
Age, gender, level of education, professional status, number of children
Time frame: Inclusion
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Attention Deficit Disorder with Hyperactivity →